Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
Complete regulatory breakdown of Evenity (romosozumab), including FDA approval history, boxed warning details, compounding legality, EMA status, and post-market safety surveillance data.
Read clinical reviewComplete FDA approval timeline for Evenity (romosozumab), including clinical trial data from FRAME and ARCH, boxed warning details, label updates, and post-market safety surveillance.
Read clinical reviewA complete timeline of Evenity (romosozumab) FDA label updates from 2020 through 2026, including the cardiovascular boxed warning, post-market safety data, and prescribing changes.
Read clinical reviewA detailed comparison of how the FDA and EMA evaluated and approved romosozumab (Evenity), including label differences, cardiovascular safety signals from the ARCH trial, and post-market surveillance requirements.
Read clinical reviewA clinical review of Evenity (romosozumab) patent disputes, FDA regulatory history, boxed warning litigation risk, and the biosimilar pathway for this monoclonal antibody osteoporosis treatment.
Read clinical review